ADC Therapeutics/$ADCT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ADC Therapeutics
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
Ticker
$ADCT
Sector
Primary listing
NYSE
Employees
264
Headquarters
Epalinges, Switzerland
Website
ADC Therapeutics Metrics
BasicAdvanced
$498M
-
-$1.58
2.01
-
Price and volume
Market cap
$498M
Beta
2.01
52-week high
$4.67
52-week low
$1.05
Average daily volume
901K
Financial strength
Current ratio
4.934
Quick ratio
4.501
Long term debt to equity
-225.407
Total debt to equity
-226.307
Interest coverage (TTM)
-2.54%
Profitability
EBITDA (TTM)
-126.139
Gross margin (TTM)
-48.55%
Net profit margin (TTM)
-220.00%
Operating margin (TTM)
-165.08%
Effective tax rate (TTM)
-0.70%
Revenue per employee (TTM)
$290,000
Management effectiveness
Return on assets (TTM)
-22.99%
Return on equity (TTM)
102.73%
Valuation
Price to revenue (TTM)
6.185
Price to book
-2.5
Price to tangible book (TTM)
-2.5
Price to free cash flow (TTM)
-3.736
Free cash flow yield (TTM)
-26.77%
Free cash flow per share (TTM)
-1.186
Growth
Revenue change (TTM)
15.73%
Earnings per share change (TTM)
-37.16%
3-year revenue growth (CAGR)
-6.32%
3-year earnings per share growth (CAGR)
-13.49%
What the Analysts think about ADC Therapeutics
Analyst ratings (Buy, Hold, Sell) for ADC Therapeutics stock.
Bulls say / Bears say
In the LOTIS-7 Phase 1b trial, ZYNLONTA combined with glofitamab achieved a 95.5% overall response rate and a 90.9% complete response rate, demonstrating strong efficacy in r/r DLBCL patients (ADC Therapeutics Q1 2025 – turn3search0).
ADC Therapeutics reached commercial brand profitability for ZYNLONTA in full-year 2024, generating $69.3 million in net product revenues, underscoring successful commercialization efforts (ADC Therapeutics FY 2024 – turn3search1).
Preclinical data presented at AACR 2025 highlighted the company’s next-generation exatecan-based ADCs targeting Claudin-6, PSMA, and ASCT2, showcasing a robust pipeline beyond ZYNLONTA (ADC Therapeutics Q1 2025 SEC Filing – turn3search3).
ADC Therapeutics’ net product revenues for ZYNLONTA declined slightly to $17.4 million in Q1 2025 from $17.8 million in Q1 2024, indicating challenges in maintaining sales volume year-over-year (ADC Therapeutics Q1 2025 – turn3search0).
The company’s GAAP net loss widened to $56.6 million in Q2 2025 from $36.5 million in the prior-year period, reflecting ongoing high cash burn despite cost-cutting measures (ADC Therapeutics Q2 2025 – turn4view0).
ADC Therapeutics announced a strategic reprioritization in June 2025, including a 30% workforce reduction and UK facility closure, suggesting potential operational disruption and loss of talent during execution of its refocused strategy (ADC Therapeutics Q2 2025 – turn4view0).
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2025.
ADC Therapeutics Financial Performance
Revenues and expenses
ADC Therapeutics Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ADC Therapeutics stock?
ADC Therapeutics (ADCT) has a market cap of $498M as of October 07, 2025.
What is the P/E ratio for ADC Therapeutics stock?
The price to earnings (P/E) ratio for ADC Therapeutics (ADCT) stock is 0 as of October 07, 2025.
Does ADC Therapeutics stock pay dividends?
No, ADC Therapeutics (ADCT) stock does not pay dividends to its shareholders as of October 07, 2025.
When is the next ADC Therapeutics dividend payment date?
ADC Therapeutics (ADCT) stock does not pay dividends to its shareholders.
What is the beta indicator for ADC Therapeutics?
ADC Therapeutics (ADCT) has a beta rating of 2.01. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.